Two Vaccines Against RSV in Older Adults Approved One Month Apart: It Happened in 2023

The seasonal respiratory syncytial virus, which claims between 6000 and 10 000 older adult lives each year, will now face significant barriers to spread in this vulnerable population the US.

The short slide show that follows provides snapshots of the headline news stories posted on Patient Care® in 2023 that traced the clinical trials and approval process for GKS's RSVPreF3 (Arexvy) and Pfizer's RSVPreF (Abrysvo).